Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Double-blind randomized placebo-controlled withdrawal study of canakinumab in systemic juvenile idiopathic arthritis
2008-005479-82Phase 3Completed
- Sponsor
- Novartis
- Start
- Mar 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of canakinumab in systemic juvenile idiopathic arthritis (SJIA) (3 arms), sponsored by Novartis. Primary endpoint: Time to flare (Part II). Started Mar 2009; status: completed.
02
Drugs
canakinumab
03
Conditions
systemic juvenile idiopathic arthritis (SJIA)
Beyond the preview
Go deeper on 2008-005479-82.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-005479-82.